NM 108

Drug Profile

NM 108

Alternative Names: NM108; NM108-MiDROPS™

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuMedics
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Collagenase inhibitors; Inflammation mediator inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Diabetic retinopathy; Eye-Disorders; Uveitis

Most Recent Events

  • 12 Jun 2015 NeuMedics announces intention to file an IND to US FDA by 2017 (NeuMedics website, June 2015)
  • 12 Jun 2015 NeuMedics plans phase IIa and III trials for Diabetic macular oedema in USA (NeuMedics pipeline, June 2015)
  • 04 May 2015 Preclinical trials in Diabetic Retinopathy, Diabetic macular oedema, Uveitis and Eye disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top